(IN201717040550) Antiviral and antibacteria agents based on quaternary ammonium compound complexed with boric acid and its derivatives 机翻标题: 暂无翻译,请尝试点击翻译按钮。

源语言标题
Antiviral and antibacteria agents based on quaternary ammonium compound complexed with boric acid and its derivatives
公开号/公开日
IN201717040550 A 2018-01-05 [IN201717040550] / 2000
申请号/申请日
2017IN-17040550 / 2017-11-14
发明人
Canh LE Tien;Giuliano LAFRENIERE DI FRUSCIA;
申请人
B ORGANIC FILMS;
主分类号
IPC分类号
A61K-031/69A61P-031/00C07F-005/05
摘要
(IN201717040550) The present document describes compounds resulting from the complexation of quaternary ammonium compounds with boric acid and/or its derivatives and methods of making the same and methods of using the same for the treatment of pathogenic infections.
机翻摘要
暂无翻译结果,您可以尝试点击头部的翻译按钮。
地址
代理人
代理机构
;
优先权号
2015US-62147161 2015-04-14
主权利要求
(IN201717040550)  1. A compound of formula I, or a pharmaceutically acceptable salts thereof, And stereoisomers thereof: 5. (I) Wherein R1, R2, R3, and R4 are independently selected from alkyl, cycloalkyl, or aryl, Optionally substituted with at one or more -OH, and 10. Each of said R1, R2, R3, and R4 may be optionally connected to another of said R1, R2, R3, and R4;  R5 is selected from -BO2, -BO3, -BO4, -B2O3, -B2O4, -B3O5, -B3O7, -B4O7, - B4O9 -B5O8, -O-BR6R7;  R6 is selected from -H, -OH, alkyl, alkenyl, aryl, -O-R8;  15. R7 is absent or selected from -H, -OH, alkyl, alkenyl, aryl, and -O-R8;  R8 is selected from -H, alkyl, alkenyl, aryl. 2. The compound of claim 1, or a pharmaceutically acceptable salts thereof, And stereoisomers thereof, wherein R1 is CH2-CH2.  20. 3. The compound of any one of claims 1 - 2, or a pharmaceutically acceptable salts thereof, and stereoisomers thereof, wherein any one of R2, R3, And R4 is independently CH3, CH2-CH3, or CH2-CH2-CH3. 25. 4. The compound of claim 1, wherein R1 is CH2-CH2, R2, R3, and R4 is independently CH3. 58. 5. The compound of any one of claims 1 to 4, wherein R5 is -B5O8. 6. The compound of any one of claims 1 to 4, wherein R5 is -O-BR6R7.  5. 7. The compound of claim 5, wherein R5 is -O-B(OH)2. 8. The compound of claim 1, wherein said compound is selected from the following compounds: 10. And, or a combination thereof. 9. The compound of claim 1, wherein said compound is a combination of the following compounds: 59.  and. 10. A pharmaceutical composition comprising a compound of any one of claims 1 to 8, or a pharmaceutically acceptable salt thereof, and a pharmaceutically a 5 cceptable carrier. 11. A composition comprising a compound of any one of claims 1 to 8, or a pharmaceutically acceptable salt thereof, and an acceptable carrier. 12. Use of a compound of any one of claims 1 to 8 or a pharmaceutically acceptable salt thereof for the manufacture of a medicament for treatment of a pathogenic infection in a subject. 13. Use of a compound of any one of claims 1 to 8, or a pharmaceutically 15. Acceptable salt thereof, or the composition of any one of claims 10 - 11, for treatment of a pathogenic infection in a subject. 60. 14. The use of any one of claims 12 to 13, wherein said subject is selected from the group consisting of a mammal, a fish, a bird, and a crustacean. 15. The use of claim 14, wherein said mammal is selected from the group consisting of a human, a bovine, an 5 equine, and an ungulate. 16. The use of claim 14, wherein said fish is selected from the group consisting of a hagfish, a lamprey, a cartilaginous fish and a bony fish. 17. The use of claim 14, wherein said bird is selected from the group consisting of chicken, a turkey, and a fowl. 18. The use of claim 14, wherein said crustacean is selected from the group consisting of a shrimp, a crab, a lobster, a langouste.  15. 19. A method of treating or preventing a pathogenic infection in a subject in need thereof comprising: - administering a therapeutically effective amount a compound of any one of claims 1 to 8, or a pharmaceutically acceptable salt thereof, or the 20. Composition of any one of claims 10 - 11, to said subject. 20. The method of claim 19, wherein said subject is selected from the group consisting of a mammal, a fish, a bird, and a crustacean. 25. 21. The method of claim 20, wherein said mammal is selected from the group consisting of a human, a bovine, an equine, and an ungulate. 22. The method of claim 20, wherein said fish is selected from the group consisting of a hagfish, a lamprey, a cartilaginous fish and a bony fish.  61. 23. The method of claim 20, wherein said bird is selected from the group consisting of chicken, a turkey, and a fowl. 24. The method of claim 20, wherein said crustacean 5 is selected from the group consisting of a shrimp, a crab, a lobster, and a langouste. 25. A method of treating or preventing a pathogenic infection in a crustacean in need thereof comprising: 10. - administering a therapeutically effective amount a compound of any one of claims 1 to 8, or a pharmaceutically acceptable salt thereof, or the composition of any one of claims 10 - 12, to said crustacean. 26. The method of claim 25, wherein said crustacean is selected from the 15. Group consisting of a shrimp, a crab, a lobster, and a langouste. 27. The method of any one of claims 25 - 26, wherein said pathogenic infection is caused by a virus, a microorganism, or combinations thereof. 20. 28. The method of claim 27, wherein said virus is one of more of White Spot Syndrome Virus (WSSV), Taura Syndrome Virus (TSV), Yellow Head Virus (YHV), Infectious Hypodermal and Haematopoietic Necrosis (IHHNV), Spherical Baculovirus, Spawner-isolated Mortality Virus Disease, Spring Viremia of Carp (SVC caused by Rhabdoviruses), Koi Herpes Virus (KHV), Large Mouth Bass Virus 25. (LMBV), and Baculovirus penaei (BP). 29. The method of claim 27, wherein said microorganism is one or more of Vibrio parahaemolyticus, Vibrio harveyi, V. splendidus, V. parahaemolyticus, V.  Alginolyticus, V. anguillarum, V. vulnificus, V. campbelli, V. fischeri, V. damsella, 62.  V. pelagicus, V. orientalis, V. ordalii, V. mediterrani, V. logei, an Enterobacteriacae, Clostridium botulinum, Listeria monocytogenes. 30. The method of claim 29, wherein said Enterobacteriacae is one or more of an Escheria 5 coli, a Salmonella, a Shigella. 31. The method of any one of claims 25 - 30, wherein administering is by feeding said compound, or said pharmaceutically acceptable salt thereof, or said composition to said crustacean.  10. 32. The composition of claim 11, wherein said composition is a dietary composition. 33. The composition of claim 11, for use in the treatment or prevention of a 15. Pathogenic infection in a crustacean in need thereof.
法律状态
(IN201717040550) LEGAL DETAILS FOR IN201717040550  Actual or expected expiration date=2037-11-14    Legal state=ALIVE    Status=PENDING     Event publication date=2017-11-14  Event code=IN/APP  Event indicator=Pos  Event type=Examination events  Application details  Application country=IN IN201717040550  Application date=2017-11-14  Standardized application number=2017IN-17040550     Event publication date=2018-01-05  Event code=IN/A  Event indicator=Pos  Event type=Examination events  Application laid open  Publication country=IN  Publication number=IN201717040550  Publication stage Code=A  Publication date=2018-01-05  Standardized publication number=IN201717040550
专利类型码
A
国别省市代码
若您需要申请原文,请登录。

最新评论

暂无评论。

登录后可以发表评论

意见反馈
返回顶部